Literature DB >> 17118126

Pharmacokinetics of ribavirin in patients with hepatitis C virus.

Janet R Wade1, Eric Snoeck, Frank Duff, Matthew Lamb, Karin Jorga.   

Abstract

AIM: A population pharmacokinetic analysis was performed using plasma concentration data (n = 7025) from 380 patients to examine the relationship between ribavirin dose and its pharmacokinetics.
METHODS: Ribavirin pharmacokinetics were described by a three-compartment model with sequential zero-order and a first-order absorption processes. Interoccasion variability and food effects were included.
RESULTS: Lean body weight (range 41-91 kg) was the only covariate with a clinically significant influence on ribavirin pharmacokinetics, affecting clearance (15.3-23.9 l h(-1)) and the volume of the larger peripheral compartment.
CONCLUSION: The model provided a good description of the available data, confirmed by accurate estimates of parameter values and low residual variability (17%).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118126      PMCID: PMC1804105          DOI: 10.1111/j.1365-2125.2006.02704.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  [Treatment of hepatitic C virus infection after the French 2002 Consensus Conference].

Authors:  P Cacoub
Journal:  Rev Med Interne       Date:  2002-11       Impact factor: 0.728

Review 2.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Authors: 
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia.

Authors:  Masato Homma; Yasushi Matsuzaki; Yoichi Inoue; Minoru Shibata; Keiji Mitamura; Naomi Tanaka; Yukinao Kohda
Journal:  Clin Gastroenterol Hepatol       Date:  2004-04       Impact factor: 11.382

4.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

5.  Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.

Authors:  M Rodriguez-Torres; F J Torriani; V Soriano; M J Borucki; E Lissen; M Sulkowski; D Dieterich; K Wang; J-M Gries; P G Hoggard; D Back
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.

Authors:  J R Wade; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

7.  Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

Authors:  Annette Bruchfeld; Karin Lindahl; Robert Schvarcz; Lars Ståhle
Journal:  Ther Drug Monit       Date:  2002-12       Impact factor: 3.681

8.  Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

Authors:  J F Jen; P Glue; S Gupta; D Zambas; G Hajian
Journal:  Ther Drug Monit       Date:  2000-10       Impact factor: 3.681

9.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

10.  Ribavirin quantification in combination treatment of chronic hepatitis C.

Authors:  Sylvie Larrat; Françoise Stanke-Labesque; Agnès Plages; Jean-Pierre Zarski; Germain Bessard; Claude Souvignet
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more
  16 in total

Review 1.  Management of patients with hepatitis C infection and renal disease.

Authors:  Chalermrat Bunchorntavakul; Monthira Maneerattanaporn; Disaya Chavalitdhamrong
Journal:  World J Hepatol       Date:  2015-02-27

2.  Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

Authors:  Eric Snoeck; Janet R Wade; Frank Duff; Matthew Lamb; Karin Jorga
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

3.  Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.

Authors:  Joseph E Rower; Eric G Meissner; Leah C Jimmerson; Anu Osinusi; Zayani Sims; Tess Petersen; Lane R Bushman; Pamela Wolfe; John G McHutchison; Shyamasundaran Kottilil; Jennifer J Kiser
Journal:  J Antimicrob Chemother       Date:  2015-05-13       Impact factor: 5.790

Review 4.  A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.

Authors:  Girish S Naik; Manoj G Tyagi
Journal:  J Clin Exp Hepatol       Date:  2012-04-12

5.  Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.

Authors:  Runyan Jin; Michael J Fossler; John G McHutchison; Charles D Howell; Thomas C Dowling
Journal:  AAPS J       Date:  2012-05-26       Impact factor: 4.009

6.  Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.

Authors:  Sven Mensing; Doerthe Eckert; Shringi Sharma; Akshanth R Polepally; Amit Khatri; Thomas J Podsadecki; Walid M Awni; Rajeev M Menon; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2016-11-03       Impact factor: 4.335

7.  Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.

Authors:  Sven Mensing; Akshanth R Polepally; Denise König; Amit Khatri; Wei Liu; Thomas J Podsadecki; Walid M Awni; Rajeev M Menon; Sandeep Dutta
Journal:  AAPS J       Date:  2015-11-23       Impact factor: 4.009

8.  Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2).

Authors:  Sook Wah Yee; James E Shima; Stephanie Hesselson; Loan Nguyen; Sarah De Val; Rachel J Lafond; Michiko Kawamoto; Susan J Johns; Doug Stryke; Pui-Yan Kwok; Thomas E Ferrin; Brian L Black; David Gurwitz; Nadav Ahituv; Kathleen M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2008-12-19       Impact factor: 4.030

Review 9.  Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.

Authors:  Susan J Keam; Risto S Cvetković
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.

Authors:  B J Brennan; K Wang; S Blotner; M O Magnusson; J J Wilkins; P Martin; J Solsky; K Nieforth; C Wat; J F Grippo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.